Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis

Author(s): V. Urquidi, C. J. Rosser, S. Goodison.

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 22 , 2012

Become EABM
Become Reviewer


The early detection of urological cancers is pivotal for successful patient treatment and management. The development of molecular assays that can diagnose disease accurately, or that can augment current methods of evaluation, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, enabling not only diagnosis of at risk patients, but also asymptomatic screening, monitoring disease recurrence and response to treatment. The advent of advanced proteomics and genomics technologies and associated bioinformatics development is bringing these goals into focus. In this article we will discuss the promise of biomarkers in urinalysis for the detection and clinical evaluation of the major urological cancers, including bladder, kidney and prostate. The development of urine-based tests to detect urological cancers would be of tremendous benefit to both patients and the healthcare system.

Keywords: Biomarkers, body fluids, diagnosis, non-invasive, urinary, urological cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [3653 - 3663]
Pages: 11
DOI: 10.2174/092986712801661103
Price: $58

Article Metrics

PDF: 14